Evidence map›Paper›PMID 37098530›Full record

ArticleBMC complementary medicine and therapies2023

Mellitin peptide quantification in seasonally collected crude bee venom and its anticancer effects on myelogenous K562 human leukaemia cell line.

Maher Obeidat, Ihab F Al-Khraisat, Da'san M M Jaradat, Bayan Y Ghanim, Qasem M Abdallah, Duaa Abu Arqoub, Duaa Sabbah, Ola M Al-Sanabra, Tawfiq Arafat, Nidal A Qinna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. The Anti-Leukemic Potential of Bee Venom.International journal of general medicine · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maher Obeidat *Department of Medical Laboratory Analysis, Faculty of Science, Al-Balqa Applied University, Al-Salt, Jordan.
Ihab F Al-Khraisat *Department of Medical Laboratory Analysis, Faculty of Science, Al-Balqa Applied University, Al-Salt, Jordan.
Da'san M M JaradatDepartment of Chemistry, Faculty of Science, Al-Balqa Applied University, Al-Salt, Jordan.
Bayan Y GhanimDepartment of Pharmacology and Biomedical Sciences, University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, Jordan.
Qasem M AbdallahDepartment of Pharmacology and Biomedical Sciences, University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, Jordan.
Duaa Abu ArqoubDepartment of Pharmacology and Biomedical Sciences, University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, Jordan.
Duaa SabbahDepartment of Pharmacology and Biomedical Sciences, University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, Jordan.
Ola M Al-SanabraDepartment of Medical Laboratory Analysis, Faculty of Science, Al-Balqa Applied University, Al-Salt, Jordan.
Tawfiq ArafatJordan Center for Pharmaceutical Research (JCPR), Amman, Jordan.
Nidal A QinnaDepartment of Pharmacology and Biomedical Sciences, University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, P.O. Box 961343, Amman, Jordan. nqinna@uop.edu.jo.
Petra University · JOAl-Balqa Applied University · JOJordan Hospital · JO

Funding

Al-Balqa' Applied University 2021/2020/497University of Petra 09/04/2020
6 · The paper itself

Abstract

backgroundApitherapy is an emerging field in cancer research, particularly in developing communities. The potency of Melittin (MEL), a major constituent in bee venom is accounted for the cytotoxic capacity against cancer cells. It is postulated that the genotype of bees and the time of venom collection influences its specific activity against certain types of cancer.

methodHereby, Jordanian crude bee venom (JCBV) was collected during different seasons of the year, specifically spring, summer and autumn and investigated for in vitro antitumour effects. Venom collected during springtime comprised the highest quantity of MEL in comparison to venom collected some other time. Springtime-collected JCBV extract and MEL were tested on an immortal myelogenous leukaemia cell line, namely K562 leukemic cells. Treated cells were examined for cell modality via flow cytometry analysis and cell death mediating gene expressions.

resultsSpringtime-collected JCBV extract and MEL showed an IC

conclusionIntegration of bee venom in chemotherapy needs more investigation and should be carefully translated into clinical use. During such translation, the correlation of bee genotype, collection time and concentration of MEL in CBV should be profiled.

Indexed as

Bee VenomsLeukemiaAnimalsBeesHumansK562 CellsMelittenPeptidesBee VenomsMelittenPeptidesApitherapyApoptosisBee venomCell arrestCytotoxicityMelittin

Identifiers

PMID37098530
PMCPMC10127481
OpenAlexW4366986426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.